18 Feb

“Comparing” vaccine COVID-19 AstraZeneca and Pfizer-BioNTech

AstraZeneca’s COVID-19 vaccine was recently included in the emergency use list by WHO with the Pfizer-BioNTech vaccine approved since December. So what do these two vaccines stand out when compared?

Effective in preventing COVID-19

According to the latest research data, the AstraZeneca -Oxford vaccine is up to 76% effective in preventing COVID-19 within 22 to 90 days after a single dose is given. Before that, interim data showed that the effectiveness of this vaccine was 70.4%.

Compared to the 95% efficacy of a two-dose vaccine from Pfizer-BioNTech, the AstraZeneca vaccine is somewhat more modest.

South Africa announced a moratorium on the AstraZeneca vaccine in its vaccination program on July 7 after a study announced it did not provide a significant effect against the risk of mild or moderate COVID-19. caused by the South African variant, symbol 501Y.V2. However, global health officials have advocated for AstraZeneca’s vaccine, saying it is too soon to conclude anything and that the vaccine will contribute to averting the COVID-19 pandemic.

The AstraZeneca vaccine has been approved for emergency use in many countries, most recently, on February 15, WHO said it has included the AstraZeneca vaccine on the global emergency list, the second being approved after Pfizer-BioNTech. in December 2020.

Differences in technology, price and storage

AstraZeneca’s COVID-19 vaccine was developed based on a “virus vector” technology , in which a weakened chimpanzee common cold virus gives genetic instructions to cells. human cells, which help fight the SARS-CoV-2 virus.

Meanwhile the vaccine Pfizer-BioNTech uses new technology mRNA to prevent viruses.

On the price front, AstraZeneca promises its vaccine will be sold non-profit for just a few dollars a dose, while the Pfizer vaccine costs between 18.40 and 19.50 dollars per dose.

Storage conditions are also one of the outstanding advantages of the AstraZeneca vaccine when it only needs to be stored in a conventional refrigerator, without the need for deep refrigeration at minus 70 degrees C like COVID-19 mRNA vaccine from Pfizer and BioNTech.

With the advantages of low cost, easy storage and transportation, AstraZeneca vaccine is better rated for its suitability in poor and underdeveloped countries. While storing and transporting vaccine Pfizer-BioNTech is a big challenge for many countries, including developed ones.

Which vaccine is ordered by more countries?

The Pfizer-BioNTech vaccine is one of the leading vaccines approved for emergency use and ordered by many countries. Countries that already pre-ordered this vaccine include: Bahrain, Canada, Chile, Dubai, Ecuador, EU, Germany, Israel, Japan, Malaysia, Mexico, the Netherlands, Panama, Peru, Spain, Switzerland Si, British, American …

AstraZeneca-Oxford’s low-cost vaccine is equally as expensive with a series of countries signing a buying agreement: Australia, Brazil, Canada, Chile, COVAX, Ecuador, EU, France, Germany, India, Israel, Italy, Japan, Malaysia , Morocco, Netherlands, Panama, Philippines, Korea, Spain, Switzerland, UK, USA, Vietnam …

Notably, AstraZeneca’s COVID-19 vaccine also accounts for a large proportion of doses in the global COVAX vaccine-sharing program, with more than 330 million doses to be deployed to poor countries from the end of February.

Immunization subjects

Pfizer-BioNTech COVID-19 vaccine is for use in people aged 16 and over. While vaccine AstraZeneca can be used with subjects over 18 years old.

However, many countries such as Switzerland, Australia, South Korea … say they are cautious in recommending the use of AstraZeneca vaccine for people over 65 years old because of insufficient data on efficacy in the elderly. .

In this regard, WHO experts have recommended that the AstraZeneca-Oxford COVID-19 vaccine be used for people over 65 years of age, and also where SARS-CoV-2 variants are of concern. current.


Leave a Reply

Your email address will not be published. Required fields are marked *